Introduction <p><i>FLNA</i> pathogenic variants lead to various congenital malformations. Pulmonary manifestations were reported in early age. In adults, few cases of emphysema were published. We aimed to assess the frequency and characteristics of emphysema in adults with a pathogenic or probably pathogenic variant in <i>FLNA</i>.</p> Method <p>We conducted a transversal single-center study. Adults with <i>FLNA</i> pathogenic variant followed in Lille University Hospital were identified among the French rare disease database BaMaRa^®. They attended medical examination, non-contrast chest CT-scan and pulmonary function tests (PFT). We collected medical history, tobacco smoking status, occupational and domestic exposures. When emphysema was identified, the PTPN6 gene was sequenced and alpha1antitrypsin deficiency searched. The primary objective of the study was to assess the frequency of emphysema. Secondary objectives were to evaluate emphysema type, distribution and extension, lung function in case of emphysema and the frequency of unexplained emphysema.</p> Results <p>Among the 29 patients identified, 10 met non-inclusion criteria, 4 declined, 5 could not be reached and so 10 patients were included. The frequency of emphysema was 70%. It was most often centrilobular and located in upper lobes (<i>n</i> = 4) with a median volume of 8.8% (IQR: 3.0–18.0%) of the total lung volume. The frequency of unexplained emphysema was estimated to be 57.1% of emphysema cases. PFT revealed airflow limitation (<i>n</i> = 3), reduced DLCO (<i>n</i> = 5) and small airway disease on IOS (<i>n</i> = 5).</p> Conclusion <p>These preliminary results suggest that adults with <i>FLNA</i> pathogenic variant frequently develop emphysema, allowing for a larger study to be considered.</p> Trial registration <p>ClinicalTrials.gov, NCT05550844, Registered 19 September 2022 <a href="https://clinicaltrials.gov/study/NCT05550844?cond=FLNA&amp;rank=1">https://clinicaltrials.gov/study/NCT05550844?cond=FLNA&amp;rank=1</a>.</p>